TY  - JOUR
AU  - Nishio, Makoto
AU  - Felip, Enriqueta
AU  - Orlov, Sergey
AU  - Park, Keunchil
AU  - Yu, Chong-Jen
AU  - Tsai, Chun-Ming
AU  - Cobo, Manuel
AU  - McKeage, Mark
AU  - Su, Wu-Chou
AU  - Mok, Tony
AU  - Scagliotti, Giorgio V
AU  - Spigel, David R
AU  - Viraswami-Appanna, Kalyanee
AU  - Chen, Zhe
AU  - Passos, Vanessa Q
AU  - Shaw, Alice T
PY  - 2019
DO  - 10.1016/j.jtho.2019.11.006
UR  - http://hdl.handle.net/10668/14760
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - The phase II, single-arm ASCEND-3 study assessed the efficacy and safety of ceritinib in anaplastic lymphoma kinase (ALK) inhibitor (ALKi)-naive patients with ALK-rearranged NSCLC who had received at least three previous lines of chemotherapy. Here,...
LA  - en
PB  - Elsevier
KW  - ALK
KW  - Ceritinib
KW  - NSCLC
KW  - Phase II
KW  - Anaplastic Lymphoma Kinase
KW  - Antineoplastic Agents
KW  - Humans
KW  - Lung Neoplasms
KW  - Protein Kinase Inhibitors
KW  - Pyrimidines
KW  - Quality of Life
KW  - Receptor Protein-Tyrosine Kinases
KW  - Sulfones
TI  - Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC.
TY  - research article
VL  - 15
ER  -